BioNTech’s Pipeline Countdown: Cash Burn, Patent Claims, and a Founder Exodus Collide

BioNTech's Q1 earnings reveal a turbulent transition: COVID vaccine sales slip, a patent war with Moderna escalates, and an oncology pipeline with no revenue yet faces a leadership vacuum.

The next few weeks will test whether BioNTech can navigate its most turbulent transition since the pandemic. On Tuesday, the German biotech reports first-quarter earnings, but the numbers are only part of a much larger story that includes a patent battle with Moderna, a looming leadership vacuum, and a high-stakes oncology pipeline that has yet to generate a single euro in revenue.

The Numbers Game

BioNTech’s 2026 revenue guidance of €2.0 billion to €2.3 billion already disappointed analysts, who had penciled in €2.75 billion on average. COVID vaccine sales are expected to slip modestly from last year, while cancer drug income remains absent from the forecast entirely. That leaves the burn rate as the key metric for investors: with €17.2 billion in cash and securities at the end of 2025, the company has ample runway, but the pace of spending will determine how long that cushion lasts.

A Legal Counterpunch

February saw BioNTech file a patent infringement suit against Moderna in Delaware, alleging that Moderna’s updated mRNA vaccine mNEXSPIKE violates a BioNTech patent covering a truncated spike-protein design that enables lower dosing. Moderna expects mNEXSPIKE to account for roughly 55% of its COVID vaccine revenue in the 2025/2026 season. BioNTech is seeking damages but notably did not request an injunction — a sign that blocking sales is not the primary objective.

The litigation is not one-sided. Moderna first sued BioNTech and its partner Pfizer over Comirnaty in 2022, and that case remains unresolved. The cross-Atlantic legal tussle adds another layer of complexity to an already crowded agenda.

Oncology Takes Center Stage

The real catalyst for the stock, however, is the cancer pipeline. BioNTech plans to launch six additional Phase 3 trials this year, bringing the total to 15. Seven data readouts are expected in the coming months, five of which could be registration-enabling.

The lead candidate is pumitamig, a bispecific immunomodulator that combines PD-L1 inhibition with VEGF-A neutralization, developed alongside Bristol Myers Squibb. BMO Capital Markets has argued that with eight registration studies underway in oncology, BioNTech could “become a commercial cancer company within the decade.”

Early data for gotistobart, a lung cancer therapy, showed a 54% reduction in the risk of death versus standard chemotherapy in a Phase 3 precursor study. The pivotal trial is ongoing. Meanwhile, trastuzumab pamirtecan, an HER2-directed antibody-drug conjugate co-developed with Duality Biologics, has received both Fast Track and Breakthrough Therapy designations from the FDA after positive Phase 2 results in advanced endometrial cancer. A regulatory submission is planned for 2026.

The Founder Factor

Overhanging all of this is the planned departure of founders Ugur Sahin and Özlem Türeci by the end of 2026. They intend to spin off into a new independent mRNA research company, with a binding agreement on technology transfer expected by the end of June. BioNTech will retain a minority stake in the new entity.

The announcement triggered a sharp selloff on March 10, with shares plunging as much as 18% to around $80. The stock has partially recovered since, but uncertainty persists. A supervisory board search for successors is underway, and the board itself is set to expand from six to eight members at the May 15 annual general meeting — a move directly tied to the succession planning.

What to Watch

With earnings due Tuesday, the AGM on May 15, and the spin-off agreement deadline looming at the end of June, BioNTech is compressing years of transformation into weeks. The market will be watching not just the cash burn rate, but whether the founders’ exit disrupts the execution of a pipeline that has never been more critical to the company’s future.